Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

A controlled trial of naloxone infusions for the pruritus of chronic cholestasis.

Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA.

Gastroenterology. 1992 Feb;102(2):544-9.

PMID:
1732125
2.

Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial.

Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmitt JM, Walker EC, Jones EA.

Ann Intern Med. 1995 Aug 1;123(3):161-7.

PMID:
7598296
3.

A controlled trial of ondansetron in the pruritus of cholestasis.

O'Donohue JW, Pereira SP, Ashdown AC, Haigh CG, Wilkinson JR, Williams R.

Aliment Pharmacol Ther. 2005 Apr 15;21(8):1041-5.

4.

Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study.

Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA.

J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):431-4.

PMID:
10459118
5.

Ondansetron and pruritus in chronic liver disease: a controlled study.

Jones EA, Molenaar HA, Oosting J.

Hepatogastroenterology. 2007 Jun;54(76):1196-9.

PMID:
17629069
6.

Pilot study of bright-light therapy reflected toward the eyes for the pruritus of chronic liver disease.

Bergasa NV, Link MJ, Keogh M, Yaroslavsky G, Rosenthal RN, McGee M.

Am J Gastroenterol. 2001 May;96(5):1563-70.

PMID:
11374700
7.

Treatment of pruritus with topically applied opiate receptor antagonist.

Bigliardi PL, Stammer H, Jost G, Rufli T, Büchner S, Bigliardi-Qi M.

J Am Acad Dermatol. 2007 Jun;56(6):979-88. Epub 2007 Feb 22.

PMID:
17320241
8.

The pathogenesis and treatment of pruritus and fatigue in patients with PBC.

Jones EA, Bergasa NV.

Eur J Gastroenterol Hepatol. 1999 Jun;11(6):623-31. Review.

PMID:
10418933
9.

Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.

Bergasa NV, Schmitt JM, Talbot TL, Alling DW, Swain MG, Turner ML, Jenkins JB, Jones EA.

Hepatology. 1998 Mar;27(3):679-84.

PMID:
9500694
10.

Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study.

Wolfhagen FH, Sternieri E, Hop WC, Vitale G, Bertolotti M, Van Buuren HR.

Gastroenterology. 1997 Oct;113(4):1264-9.

PMID:
9322521
11.

Opiate antagonist therapy for the pruritus of cholestasis: the avoidance of opioid withdrawal-like reactions.

Jones EA, Neuberger J, Bergasa NV.

QJM. 2002 Aug;95(8):547-52. Review.

PMID:
12145394
12.

Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial.

Müller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, Raderer M, Scheithauer W, Ferenci P.

Eur J Gastroenterol Hepatol. 1998 Oct;10(10):865-70.

PMID:
9831410
13.
14.

Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

Turner IB, Rawlins MD, Wood P, James OF.

Aliment Pharmacol Ther. 1994 Jun;8(3):337-42.

PMID:
7918930
15.
17.

Naloxone for intractable pruritus?

Zuckerman E, Schar M, Korula J.

Am J Gastroenterol. 1997 Jan;92(1):183-4. No abstract available.

PMID:
8995978
18.

Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.

Pauli-Magnus C, Mikus G, Alscher DM, Kirschner T, Nagel W, Gugeler N, Risler T, Berger ED, Kuhlmann U, Mettang T.

J Am Soc Nephrol. 2000 Mar;11(3):514-9.

19.

Low-dose naloxone does not improve morphine-induced nausea, vomiting, or pruritus.

Greenwald PW, Provataris J, Coffey J, Bijur P, Gallagher EJ.

Am J Emerg Med. 2005 Jan;23(1):35-9.

PMID:
15672335
20.

The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus.

Tandon P, Rowe BH, Vandermeer B, Bain VG.

Am J Gastroenterol. 2007 Jul;102(7):1528-36. Epub 2007 Mar 31. Review.

PMID:
17403073

Supplemental Content

Support Center